Searched for
RANJIT KAPADIA
Past issues, heavy attrition at the root of Ranbaxy’s problems: Ranjit Kapadia, Centrum Broking"We have a 'sell' rating with a target price of Rs 360. Now we have to watch the situation today as it unfolds and accordingly, we will tak...24 Jan, 2014, 01.12 PM IST- Wockhardt dogged by regulatory issues, prefer Aurobindo Pharma instead: Ranjit Kapadia"Wockhardt has been languishing for some time now, whereas in case of Aurobindo, there is a steady flow of news on the launch of their gene...20 Dec, 2013, 02.56 PM IST
- Pfizer, Wyeth merger to add more value to stocksIndian units of global drug majors Pfizer and Wyeth have been star performers on Dalal Street, notching up gains of nearly 55% and 60%, res...27 Nov, 2013, 09.54 AM IST
- Pfizer-Wyeth merger good for shareholders: Ranjit Kapadia, Centrum BrokingIn an interview with ET Now, Ranjit Kapadia, Sr VP-Pharma, Centrum Broking Ltd, shares his views on the Pfizer-Wyeth merger.25 Nov, 2013, 01.16 PM IST
- Ranbaxy gains momentum as SC rejects PILRanjit Kapadia, Senior VP, Centrum Broking doesn’t expect too much upside in the stock. The outcome was on expected lines, he said to ET No...25 Jun, 2013, 11.51 AM IST
- Ranbaxy can only sell US-made Lipitor copyThe US Food and Drug Administration has allowed Ranbaxy to manufacture generic Lipitor at Ohm Labs facility in the US for American market.05 Mar, 2013, 07.28 AM IST
- Lupin’s numbers are below expectations: Ranjit Kapadia, Centrum BrokingIn an interview with ET Now, Ranjit Kapadia, Sr VP Institutional Research, Centrum Broking Pvt Ltd, gives his views on Lupin’s Q2 earnings....23 Oct, 2012, 04.50 PM IST
- Sun Pharmaceuticals spins off home formulation businessThe move sparked a fair bit of speculation on the domestic unit, and a range of theories - like bringing in a foreign partner to a possible...11 Aug, 2012, 11.58 AM IST
- Ranbaxy Q1 net profit up four-fold to Rs 1,246 crRanbaxy Laboratories, India's largest drugmaker by sales, beat market expectations with a four-fold jump in first-quarter net profit, drive...10 May, 2012, 05.26 AM IST
- Dr Reddy's Laboratories splits marketing divisionDr Reddy's Laboratories (DRL) has split a key marketing division into two parts in a bid to resurrect its ailing domestic business.24 Dec, 2011, 04.48 AM IST
- Pfizer fights to retain Lipitor market shareThe move is expected to hit Ranbaxy Pharma, which has the exclusive rights to sell the generic version for three months beginning November ...24 Nov, 2011, 02.22 AM IST
- Wockhardt: Will investors forgive the company?Forget its financial and legal woes, Habil Khorakiwala wants the world to notice that Wockhardt is on the road to recovery.03 Mar, 2011, 01.40 PM IST
- Fortis promoters offer to buy rest of Parkway stakeFortis Healthcare has decided to counter Khazanah with an offer for Parkway Holdings that is slightly more than that of Malaysian fund. Ful...02 Jul, 2010, 06.00 AM IST
- GIC postpones plan to invest in Fortis sharesApollo Hospitals, in which Khazanah owns about 12% stake, has indicated its backing of Malaysian sovereign fund's move. 'Vote against Khaza...26 Jun, 2010, 06.28 AM IST
- Lupin Q4 net surges 40 pcPharmaceutical company Lupin said on Wednesday its fourth quarter net profit rose 40% on account of lower raw material costs and strong sal...06 May, 2010, 02.36 AM IST
- Cipla mops up Rs 671 cr through QIPIndian generics drug maker Cipla has raised $140 million (nearly Rs 671 crore) through a qualified institutional placement (QIP) of shares ...24 Sep, 2009, 12.40 AM IST
- SC seeks Environment ministry's report on two mining firmsThe Supreme Court sought an explanation from the Ministry of Environment and Forests on the criteria it adopted while granting "environment...25 Oct, 2007, 10.10 PM IST
Load More
